Rapport Therapeutics, Inc. (RAPP) Cash Flow Statement
Rapport Therapeutics, Inc. (RAPP) generated -$96.7M of operating cash flow over the twelve months to 2026-06-30, spent $467000 on capital expenditure and had free cash flow of -$97.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAPPRapport Therapeutics, Inc.Follow RAPP — free
—
Price chart with a free account
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -64.8 | -87.5 | -96.7 | |
| Capital expenditure | 2.4 | 0.6 | -0.5 | |
| Free cash flow | -67.2 | -88.1 | -97.1 | |
| Stock-based compensation | 10.2 | 18.9 | — |
USD millions · SEC XBRL
Rapport Therapeutics, Inc. — questions
- What is Rapport Therapeutics, Inc.'s operating cash flow?
- -$96.7M over the twelve months to 2026-06-30.
- How much does Rapport Therapeutics, Inc. spend on capital expenditure?
- $467000 over the twelve months to 2026-06-30.
- What is Rapport Therapeutics, Inc.'s free cash flow?
- -$97.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Rapport Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.